OTC: HMDCF - HUTCHMED (China) Limited

六个月盈利: -15.99%
股息率: 0.00%
部门: Healthcare

促销时间表 HUTCHMED (China) Limited


关于公司 HUTCHMED (China) Limited

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.

更多详情
It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.hutch-med.com
Цена ао 3.82
每日价格变化: 0% (3.205)
每周价格变化: 0% (3.205)
每月价格变化: -15.99% (3.815)
3个月内价格变化: -15.99% (3.815)
六个月内的价格变化: -15.99% (3.815)
每年价格变化: -15.99% (3.815)
3年内价格变化: -37.28% (5.1097)
5年内价格变化: -47.55% (6.11)
10年价格变化: 0% (3.205)
年初以来价格变化: -15.99% (3.815)

低估

姓名 意义 年级
P/S 3.95 4
P/BV 4.46 4
P/E 32.9 5
EV/EBITDA 121.88 1
全部的: 5.38

效率

姓名 意义 年级
ROA, % 7.88 2
ROE, % 13.8 4
全部的: 2

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0.8714

责任

姓名 意义 年级
Debt/EBITDA 3.25 4
全部的: 8.6

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 308.98 10
盈利能力 Ebitda, % -149.91 0
盈利能力 EPS, % -172.78 0
全部的: 2



导师 职称 支付 出生年份
Dr. Wei-Guo Su B.Sc., Ph.D. CEO, Chief Scientific Officer & Executive Director 2.45M 1958 (67 年)
Mr. Chig Fung Cheng BEc, CA CFO & Executive Director 962.15k 1967 (58 年)
Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E Company Secretary & Non-Executive Director N/A 1952 (73 年)
David Ng Head of Investor Relations & Capital Strategies N/A
Mr. Charles George Rupert Nixon Group General Counsel N/A 1970 (55 年)
Mr. Kin Hung Lee M.B.A. Senior Vice President of Corporate Management & Communications N/A 1977 (48 年)
Ms. Selina Zhang Senior Vice President of Global Human Resources N/A
Dr. Qingmei Wang Ph.D. Senior Vice President of Business Development & Strategic Alliances N/A 1963 (62 年)
Ms. Yiling Cui Executive VP & Head of Operations N/A
Mr. Hong Chen Executive VP & Chief Commercial Officer- China N/A 1970 (55 年)

地址: Hong Kong, Central, Cheung Kong Center - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.hutch-med.com